Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Genetics

How Does Genetic Subtype Affect Angelman Syndrome Symptoms?

At a Glance

The genetic subtype of Angelman syndrome significantly impacts symptom severity. The most common subtype, maternal deletion, typically causes more severe symptoms, including earlier seizures and slower motor development. Non-deletion subtypes usually result in slightly milder developmental symptoms.

If your child’s genetic report indicates a maternal deletion (a missing piece of the 15th chromosome inherited from the mother), it helps to know that while this subtype is generally associated with more significant medical and developmental challenges, understanding these specifics allows you to build a highly targeted care plan [1]. Children with a maternal deletion often experience an earlier onset of seizures and may take longer to reach physical milestones than children with other subtypes [2][3]. However, every child’s timeline is unique, and early, tailored intervention can make a meaningful difference in their quality of life.

Why Subtypes Matter

Angelman syndrome is caused by a loss of function in the UBE3A gene on the 15th chromosome [4]. However, how that gene loses its function varies, creating different genetic “subtypes.” Knowing your child’s subtype is important for two main reasons: it helps predict their clinical and developmental path, and it determines the likelihood of having another child with Angelman syndrome (recurrence risk) [5]. For example, the risk of recurrence for a spontaneous maternal deletion or UPD is usually less than 1%, while the risk for inherited UBE3A mutations can be as high as 50%. A genetic counselor can help clarify what this means for your family.

There are four main genetic subtypes:

  • Maternal Deletion: A piece of the 15th chromosome inherited from the mother is missing.
  • Paternal Uniparental Disomy (UPD): The child inherits two copies of the 15th chromosome from the father and none from the mother.
  • Imprinting Defect: Both parents’ chromosomes are present, but the maternal copy is “turned off” or inactive.
  • UBE3A Mutation: The UBE3A gene is present but altered so it does not work correctly.

The Maternal Deletion Subtype

Maternal deletion is the most common subtype. Because the missing piece of the chromosome often includes not just the UBE3A gene but also neighboring genes, this subtype typically presents with more severe symptoms [2][6].

  • Seizures: Epilepsy is a core feature across all subtypes, but children with a deletion often experience seizures at an earlier age, and the seizures can be more severe and lead to more frequent hospitalizations [7][8]. The loss of neighboring genes related to GABA receptors (which help calm nerve activity in the brain) likely contributes to this higher risk [6][9].
  • Head Growth: Children with a deletion have a higher risk of developing microcephaly (a condition where the head size is smaller than expected), which is closely tracked during pediatric wellness checks [10].
  • Developmental Milestones: While research shows almost all individuals with Angelman syndrome can learn to walk with support by five years of age, those with a deletion often take longer to achieve independent walking and daily living skills compared to those with other subtypes [3][11].
  • Class I vs. Class II Deletions: Within this group, the size of the missing genetic piece matters. A Class I deletion (a larger missing piece) is often associated with slightly more severe cognitive and developmental symptoms than a Class II deletion (a slightly smaller missing piece) [12][13]. You can ask your geneticist which class your child has.

Non-Deletion Subtypes (UPD, Imprinting Defects, and UBE3A Mutations)

Subtypes where the chromosome structure is mostly intact but the UBE3A gene is not functioning generally result in slightly milder symptoms [14][1].

  • Motor and Life Skills: Children with non-deletion subtypes generally achieve developmental milestones earlier and show higher scores in cognitive and motor assessments compared to children with a deletion [3][5].
  • Communication: Severe speech impairment is universal; most individuals with Angelman syndrome will rely on non-verbal communication [1][15]. However, those with non-deletion subtypes often display a higher motivation for social contact and more frequent use of symbolic communication, such as gestures or communication devices [16]. In very rare cases, individuals with mosaic imprinting defects (where only some cells carry the genetic change) may develop a vocabulary of up to 100 words and the ability to speak in short sentences [17][18].

Moving Forward and Proactive Care

Knowing your child’s specific subtype is a powerful tool for your care team. If your child has a maternal deletion, proactive monitoring for seizures is crucial. This doesn’t mean living in fear, but rather knowing what to look for—such as unusual eye fluttering, sudden drops in head control, staring spells, or rhythmic jerking movements. Discuss a schedule for routine EEGs (brain wave tests) with your neurologist, and prioritize early intervention therapies (physical, occupational, and speech) tailored to your child’s expected developmental timeline.

Common questions in this guide

Why does the maternal deletion subtype of Angelman syndrome cause more severe symptoms?
Maternal deletions often involve the loss of neighboring genes alongside the UBE3A gene. The loss of these additional genes, particularly those related to GABA receptors in the brain, can lead to earlier seizures and more pronounced developmental challenges.
What is the difference between a Class I and Class II maternal deletion?
The difference relates to the size of the missing genetic piece on the 15th chromosome. A Class I deletion involves a larger missing section and is often linked to slightly more severe cognitive and developmental symptoms than a slightly smaller Class II deletion.
Are seizures more common in certain Angelman syndrome subtypes?
While epilepsy is a core feature across all subtypes, children with a maternal deletion typically experience seizures at an earlier age. These seizures can also be more severe and lead to more frequent hospitalizations compared to those seen in non-deletion subtypes.
Will a child with Angelman syndrome learn to speak?
Severe speech impairment is universal, and most individuals rely on non-verbal methods like gestures or communication devices. However, children with non-deletion subtypes often display a higher motivation for symbolic communication, and very rare mosaic cases may develop a limited vocabulary.
Does the genetic subtype affect the risk of having another child with Angelman syndrome?
Yes, the recurrence risk varies significantly by subtype. Spontaneous maternal deletions or paternal uniparental disomy (UPD) usually have a recurrence risk of less than 1%, whereas inherited UBE3A mutations can have up to a 50% risk of recurring in future pregnancies.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific class of maternal deletion (Class I or Class II) does my child have, and how does that impact their care plan?
  2. 2.Given our child's specific subtype and risk for early seizures, how frequently should we schedule routine EEGs?
  3. 3.What subtle seizure signs (like eye fluttering or staring spells) should I watch for at home in an infant or toddler?
  4. 4.What specific early intervention therapies (like physical or occupational therapy) should we prioritize to support their motor skill development?
  5. 5.How should we approach baseline monitoring for microcephaly at their upcoming wellness checks?
  6. 6.When should we introduce Augmentative and Alternative Communication (AAC) devices given their expected speech trajectory?
  7. 7.What is the recurrence risk for our family based on this specific genetic subtype, and should we consult a genetic counselor?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Genotype-Phenotype Correlations in Angelman Syndrome.

    Yang L, Shu X, Mao S, et al.

    Genes 2021; (12(7)) doi:10.3390/genes12070987.

    PMID: 34203304
  2. 2

    An overview of health issues and development in a large clinical cohort of children with Angelman syndrome.

    Bindels-de Heus KGCB, Mous SE, Ten Hooven-Radstaake M, et al.

    American journal of medical genetics. Part A 2020; (182(1)):53-63 doi:10.1002/ajmg.a.61382.

    PMID: 31729827
  3. 3

    Developmental milestones and daily living skills in individuals with Angelman syndrome.

    Sadhwani A, Powers S, Wheeler A, et al.

    Journal of neurodevelopmental disorders 2024; (16(1)):32 doi:10.1186/s11689-024-09548-7.

    PMID: 38879552
  4. 4

    Generation of three iPSC lines with inducible systems to be used in Angelman syndrome research.

    Haake J, Kaufmann M, Steenpass L

    Stem cell research 2024; (78()):103454 doi:10.1016/j.scr.2024.103454.

    PMID: 38843694
  5. 5

    Angelman syndrome genotypes manifest varying degrees of clinical severity and developmental impairment.

    Keute M, Miller MT, Krishnan ML, et al.

    Molecular psychiatry 2021; (26(7)):3625-3633 doi:10.1038/s41380-020-0858-6.

    PMID: 32792659
  6. 6

    Electrophysiological Phenotype in Angelman Syndrome Differs Between Genotypes.

    Frohlich J, Miller MT, Bird LM, et al.

    Biological psychiatry 2019; (85(9)):752-759 doi:10.1016/j.biopsych.2019.01.008.

    PMID: 30826071
  7. 7

    Clinical Characterization of Epilepsy in Children With Angelman Syndrome.

    Cassater D, Bustamante M, Sach-Peltason L, et al.

    Pediatric neurology 2021; (124()):42-50 doi:10.1016/j.pediatrneurol.2021.08.007.

    PMID: 34536900
  8. 8

    Impact of Deletion on Angelman Syndrome Phenotype Variability: Phenotype-Genotype Correlation in 97 Patients with Motor Developmental Delay.

    Belghiti HD, Abbassi M, Sayel H, et al.

    Journal of pediatric genetics 2024; (13(1)):15-21 doi:10.1055/s-0042-1751268.

    PMID: 38567176
  9. 9

    Angelman syndrome - insights into a rare neurogenetic disorder.

    Buiting K, Williams C, Horsthemke B

    Nature reviews. Neurology 2016; (12(10)):584-93 doi:10.1038/nrneurol.2016.133.

    PMID: 27615419
  10. 10

    Angelman syndrome in Hong Kong Chinese: A 20 years' experience.

    Luk HM, Lo IF

    European journal of medical genetics 2016; (59(6-7)):315-9.

    PMID: 27174604
  11. 11

    Hyperphagia, Growth, and Puberty in Children with Angelman Syndrome.

    Bindels-de Heus KGCB, Hagenaar DA, Dekker I, et al.

    Journal of clinical medicine 2023; (12(18)) doi:10.3390/jcm12185981.

    PMID: 37762921
  12. 12

    Clinical and genetic aspects of the 15q11.2 BP1-BP2 microdeletion disorder.

    Butler MG

    Journal of intellectual disability research : JIDR 2017; (61(6)):568-579 doi:10.1111/jir.12382.

    PMID: 28387067
  13. 13

    Magnesium Supplement and the 15q11.2 BP1-BP2 Microdeletion (Burnside-Butler) Syndrome: A Potential Treatment?

    Butler MG

    International journal of molecular sciences 2019; (20(12)) doi:10.3390/ijms20122914.

    PMID: 31207912
  14. 14

    Developmental Skills of Individuals with Angelman Syndrome Assessed Using the Bayley-III.

    Sadhwani A, Wheeler A, Gwaltney A, et al.

    Journal of autism and developmental disorders 2023; (53(2)):720-737 doi:10.1007/s10803-020-04861-1.

    PMID: 33517526
  15. 15

    Communication in Angelman syndrome: a scoping review.

    Pearson E, Wilde L, Heald M, et al.

    Developmental medicine and child neurology 2019; (61(11)):1266-1274 doi:10.1111/dmcn.14257.

    PMID: 31074506
  16. 16

    Refining the Behavioral Phenotype of Angelman Syndrome: Examining Differences in Motivation for Social Contact Between Genetic Subgroups.

    Heald M, Adams D, Walls E, Oliver C

    Frontiers in behavioral neuroscience 2021; (15()):618271 doi:10.3389/fnbeh.2021.618271.

    PMID: 33664655
  17. 17

    Atypical Angelman syndrome due to a mosaic imprinting defect: Case reports and review of the literature.

    Le Fevre A, Beygo J, Silveira C, et al.

    American journal of medical genetics. Part A 2017; (173(3)):753-757 doi:10.1002/ajmg.a.38072.

    PMID: 28211971
  18. 18

    Methylation analysis and developmental profile of two individuals with Angelman syndrome due to mosaic imprinting defects.

    Baker EK, Merton CF, Tan WH, et al.

    European journal of medical genetics 2022; (65(4)):104456 doi:10.1016/j.ejmg.2022.104456.

    PMID: 35218942

This page provides educational information about Angelman syndrome genetic subtypes and symptom severity. It does not replace professional medical advice from your child's geneticist or pediatric neurologist.

Get notified when new evidence is published on Angelman syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.